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t;}~~ra Jamil, Sabia Rafi,* Hammad Hussain• and Kamran 
~- 'i"';:--' d"'* ttf?itl"" ~},~ons are responsible for 30% to 50% of the morbidity and 
t¥ortality in pallents w1th system1c lupus erythematosus 
!f: ~LE), and have often been cited as the primary cause of 
!J'iiieath (34% to 66%).1 This is due to impaired neutrophil, 
~~,:~a,Crophage/ T-cell and splenic function, complement 
~Jbnonnalities and defective humoral immunity.! The risk 
ft~fuetors for infection in SLE include active lupus, renal 
;d}jristlfficiency, proteinuria, low albumin, use of corticosteroid 
;n~-riftCimununosuppressive agent.2 
"'·!"'"-'· '?fJri~ study describes the spectrum of infections in SLE 
:-_-~d_ -their association with the use of common 
:fiifununosuppressants like corticosteroids and azathioprine. 
''AU patients fulfilling the diagnostic criteria of systemic lupus 
~;'erythematosus' who were admitted to The Aga Khan 
; University Hospital, a tertiary care· referral center in Karachi, 
:·: P~kistan, from January 1992 to January 2002 were included in 
this observational study. 
{aver a period of 10 years, 80 admissions (23.8%) were for 
'!'management of 96 episodes of infections in 69 patients. There 
. M,re67 females and 2 males with a mean age of 30.9 years 
(rl\flge 8-65 years). The mean duration of lupus in these 
.·.patients was 41.7 months (SO ± 57.84). Infections were 
·,Jiagnosed on the basis of clinical presentation, laboratory 
'.·t.sts, and cultures of blood, urine, cerebrospinal fluid and 
·other relevant samples and supported by radiological 
investigations. The mean duration of hospital stay for 
management of infection was 5.16 days (SO± 5.24, range 1-25 
d~ys). Eleven patients (15.94%) had polymicrobial infections, 
· ~d infections involving more than one site. The sites of 
'illfection are shown in Table I. 
,.Bacterial infections accounted for more than 50% of all 
:infectious episodes. Staphylococcus (S.) aureus was the commonest 
~rganism isolated, followed by Escherichia coli and Klebsiella spp. 
·Four patients developed tuberculosis while receiving 
.. 10-30 mg/ day of prednisolone; one had also received pulse 
therapy with methylprednisolone 3 months before 
;_developing TB. 
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Sepsis due to Candida aJbicans (3) and Aspergillus flavus (1) was seen 
in patients receiving 40-60 mg/ day of prednisolone. These 
patients also had coexisting diabetes mellitus and renal 
failure; 2 out of 4 patients with fungal infections recovered 
Three patients had enteric fever and one had Salmonella 
typbimurium gastroenteritis. All were on 5-10mg of prednisolone 
per day for 2 2 months. Two of these patients were on 
azathioprine 100 rng/ day for 2 6 months in addition to 
prednisolone. 
The white blood cell count (WBC) was recorded for 12 patients 
out of 14 who were not on immunosuppressive therapy within 
three months of development of infection. The mean WBC 
count before admission was 6005/mm3, SO ± 1747, and at 
the onset of infection was 11,075/mm', SO ± 8'22.7 (mean 
difference 5070, SO± 7610, C.L 234.27-9905.73, p-value: 0.04, 
paired Hest). 
Fourteen patients had leucopenia on admission (total white 
cell count <4000/mm'). Of these 2 had Herpes zoster, 2 had 
malaria, 2 had cholera, and 2 had S. aureus skin infection. Tw~ 
patients had sepsis with Candida and BHS group A each. One 
patient was significantly leucopenic (WBC<1000mm') with 
WBC count of 700/mm' and absolute neutrophil count (AN C) 
of 343/mm3. This patient had meningitis with cerebrospinal 
fluid cultures positive for Aspergillus flavus. 
The ESR was recorded only for 8 patients within the three 
months prior to admission. A significant difference was found 
in mean ESR before (30 mm/hr SO± 13.0) and at the onset 
of infection in patients when the value was available for 
comparison (91.13, so ± 40.25, mean difference 54.88, cr. 
21.21-88.54, p-value: 0.006). 
In 55 out of 80 admissions (68. 75o/o ), patients were on steroid 
(oral prednisolone) therapy. The mean duration of steroid use 
was 3.38 months (SO ± 2.23 ). The maximum number of 
admissions for infections was seen in patients taking steroids 
for less than 6 months, 33/80 (41.25 o/o). 
No significant association was found between the steroid 
dosage and number of admissions for infection. A significant 
association was found between steroids dose and duration of 
admission for infections; patients on higher doses of 
prednisolone (30-60mg per day) had significantly longer 
length of hospital stay as opposed to patients taking less than 
30mg prednisolone per day (p-value 0.049 by one way 
ANOVA) . 
The mean duration of azathioprine therapy was 4.96 months 
(SO ± 1.96). The maximum number of admissions for 
Table 1: Sites of infection in SLE patients. 
Infection sites 
Lungs and pleura 
Skin and soft tissues 
Sepsis/Bacteremia 
Urinary tract 
Gastrointestinal tract 
Bone and joints 
Central nervous system /meninges 
Throat and ear 
Endometrium 
Number of infections (96) 
24 
17 
16 
15 
8 
8 
6 
625 
infections was seen in patients taking azathioprine for less 
than 6 months (13/80, 16.25%) and 2 each for patients on 
therapy for 6-12 and 12-24 months. 
No correlation was found between infection and dose and 
duration of azathioprine. 
Fourteen patients (20.28%) were not on any immuno-
suppressive agents at the time of admission for infection. 
Thirteen out of 69 patients (18.84 %) died during the course of 
infection. The rest were discharged home on appropriate 
antimicrobial therapy. 
Most infections in the study patients were due to common 
bacteria like Escherichia coli and Staphylococcus aureus. However, some 
cases of tuberculosis, malaria, salmonellosis and cholera were 
also seen. Increased incidence of salmonellosis has been 
described in SL£5 and infections by non-typhoidal Salmorwlla 
occur mainly in those SLE patients who have lower levels of 
complement, splenic dysfunction and those receiving 
immunosuppressive therapy.6 Mycobacteria, esp. M. tuberculosis 
are important opportunistic infections in SLE patients, 
particularly in endemic countries.' Serious mycobacterial 
infection necessitating hospitalization occurred in 4 patients 
and was caused exclusively by Mycobacten'um tuberculosis, a 
reflection of disease endemicity. 
Fungal infections occur frequently in SLE patients receiving 
high doses of corticosteroids or immunosuppressive 
therapy.s Fungal infections accounted for 4% of all infectious 
episodes in our patients. Aspergillus jlavus meningitis, a rare 
infection, was seen in a patient who was neutropenic and on 
high doses of corticosteroids. Herpes zoster, the most 
frequent viral infection reported in SLE 8,9 occurs mainly in 
patients with previous histories of nephritis, hemolytic 
anemia, thrombocytopenia, and previous use of 
cyclophosphamide.lO Localized zoster accounted for 3% of all 
infections in our study. It has been described to occur during 
periods of disease quiescence and in patients receiving 20mg 
or less of prednisone per day to as was seen in this study. 
Parasitic infections, which have been described in SLE, 
include encephalitis caused by Toxoplasma gondii and 
disseminated strongyloidiasis and leishmaniasis.9 Three 
percent of all infections in the present series were due to 
parasites, which are generally not considered opportunistic, 
again suggesting local prevalence rather than profound 
disease-induced inununosuppression as the predominant 
factor. 
The use of corticosteroids has been associated with increased 
occurrence of infections in patients with SLE.4,9 It is not clear, 
however, whether this risk relates to doses larger than 10 mg 
per day, incremental doses of corticosteroids, or the use of the 
intravenous route.4 Corticosteroids may not be "all bad" in 
terms of their effects on immune function in SLE.l 
Corticosteroids, by suppressing abnormally functioning cells, 
may actually improve the function of the rest of immune 
system. The dual role of corticosteroid treatment may explain 
why most studies have not found an adverse effect of 
methylprednisolone pulse therapy on the risk for infe . 
The role of azathioprine in predisposing to infecti Ction.t 
remains unclear. on also 
The outcome of infectiqns in these patients was ge 
favorable and a significant majority (81.15%) was sentn~ra~ 
after initial in-hospital management of their infection. Se 011\' 
infections developed in patients with SLE of more than 3 nou, 
duration, most of whom were not taking more than lOmgj~~ 
of prednisolone for less than 6 months. Only a 1 Y 
patients were on concomitant high dose azathiop •w 
b . . . -These o servahons suggest that m these patients, infections 
developed most likely as a consequence of irnm 
abnormalities due to the disease itself with only a rn:;,n, 
'bu . fr . f or contn t10n om concomitant use o routine immu 
. no. 
suppressants used to control the diSease. Use of higher do 
of steroids did not appear to predispose to infections requi: 
hospitalization but did increase the length of hospital stag 
Increased predisposition to infection was not seen in patieni' 
on high doses of azathioprine. s 
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